title: The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board.
abstract: The Industry Scientific Advisory Board (ISAB) consists of representatives from the private companies and nonprofit foundations participating as sponsors of Alzheimer's Disease Neuroimaging Initiative (ADNI). Currently 21 companies are represented including pharmaceutical, imaging, and biotech concerns, and two foundations including the Alzheimer's Association. ISAB members meet regularly by teleconference or face-to-face at ADNI meetings and participate in the ADNI Core groups, all administered and organized by the Foundation for the National Institutes of Health. ISAB 'deliverables' include dissemination of information to sponsors, assisting in scientific review of protocols and results, initiation and consideration of "add-on" studies and analyses, and generation of consensus positions on industry priorities and concerns. Although positioned as an advisory body, ISAB also actively contributes to the ADNI mission of identifying biomarkers of disease progression.
authors.affiliation: Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium. mschmid4@its.jnj.com
authors.forename: Mark E
authors.initials: ME
authors.lastname: Schmidt
authors.forename: Eric
authors.initials: E
authors.lastname: Siemers
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Snyder
authors.forename: William Z
authors.initials: WZ
authors.lastname: Potter
authors.forename: Patricia
authors.initials: P
authors.lastname: Cole
authors.forename: Holly
authors.initials: H
authors.lastname: Soares
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis*; D003072:Cognition Disorders / Q000175:diagnosis; D003253:Consultants; D003952:Diagnostic Imaging; D006801:Humans; D007221:Industry; D011446:Prospective Studies; D014481:United States